Our website is currently experiencing a technical issue that is causing it to load very slowly. We are working to resolve the problem as soon as possible and apologize for the inconvenience.
Open Alveolar Soft Part Sarcoma Clinical Trials Summer 2026
Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma (Recruiting) ClinicalTrials.gov ID: NCT07548177 Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial (Recruiting) ClinicalTrials.gov ID NCT05333458 A Study to Determine the Safety and […]
A New Treatment Approach for ASPS: “GCAR1” CAR T-Cell Therapy
A peer-reviewed study published in Nature Cancer describes GCAR1, an experimental CAR T-cell therapy that targets a protein called GPNMB, found on alveolar soft-part sarcoma (ASPS) and a rare form of kidney cancer. CAR-T (Chimeric Antigen Receptor T-cell therapy) is an immunotherapy in which patient’s own immune cells are engineered to kill the patient’s own […]
Please donate to support our Fight to Find a Cure for Alveolar Soft Part Sarcoma (ASPS)
Dear ASPS Community, Please support our Fight to Find a Cure for Alveolar Soft Part Sarcoma (ASPS). On August 2-3, 2025, Team ASPS participated in the Pan-Massachusetts Challenge (PMC) for the 22nd time, riding 162 miles, from Wellesley to Provincetown. The PMC is a bike-a-thon that crosses Massachusetts to raise funds for cancer research and […]
Help Cure ASPS: Sponsor Team ASPS Bike Ride at the Pan-Massachusetts Challenge 2024
Dear ASPS community, Last weekend August 3-4, 2024 Team ASPS rode for the 21st time the Pan-Massachusetts Challenge (PMC). I am asking you to sponsor our 85-mile bike ride and sponsor research at the Dana Farber Cancer Institute that aims to bring more therapies for ASPS. Twenty-one years have passed since my middle daughter was […]
The Rare Cancer Research Foundation is Partnering with iCureASPS: Please Help Find a Cure – Donate Your ASPS Tumor
The Rare Cancer Research Foundation (RCRF) is a 501(c)3 dedicated to curing rare cancers through strategic investments and innovative collaborations that facilitate effective research and accelerate deployment of promising therapies. RCRF initiated Pattern.org. If you are going to have a surgery to remove your Alveolar Soft Part Sarcoma tumor: either your primary tumor or metastatic […]
New Therapeutic Targets in Alveolar Soft Part Sarcoma Described in a New Publication
New Therapeutic Targets in Alveolar Soft Part Sarcoma were revealed in a new study conducted by Dr. Ewa Sicinska from the Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, and Dr. Matt Hemming from the Department of Medicine, Division of Hematology and Oncology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA. […]
iCureASPS is Marking 20 Years of Activity
The first weekend of August 2023 is marking 20 years of iCureASPS efforts to find a cure for Alveolar Soft Part Sarcoma (ASPS). This weekend “Team ASPS” will ride for the 20th time at the PMC bike ride. Please donate and support our efforts to find a cure for ASPS. Through Saturday and Sunday, August […]
FDA Grants Approval to Atezolizumab for Alveolar Soft Part Sarcoma
On December 9, 2022, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS). Efficacy was evaluated in Study ML39345 (NCT03141684), an open-label, single-arm study in 49 adult and pediatric patients with unresectable or […]
Summer 2022: Updated Clinical Research on Alveolar Soft Part Sarcoma
Below are links to eighteen publications describing clinical studies of ASPS with novel treatments as well as preclinical information on ASPS. The ASPS community is thankful to all the Principle Investigators, Oncologists and Researchers who are working with us to find a cure for ASPS! Anlotinib with Toripalimab for ASPS Therapy Complete Response of Metastatic […]